Buch, Englisch, 546 Seiten, Paperback, Format (B × H): 216 mm x 279 mm, Gewicht: 1257 g
Reihe: Plunkett's Industry Almanacs
Buch, Englisch, 546 Seiten, Paperback, Format (B × H): 216 mm x 279 mm, Gewicht: 1257 g
Reihe: Plunkett's Industry Almanacs
ISBN: 978-1-62831-450-2
Verlag: Plunkett Research, Ltd.
Plunkett's Biotech & Genetics Industry Almanac is a complete reference guide to the business side of biotechnology, genetics, proteomics and related services. This new book contains complete profiles of the leading biotech companies; in-depth chapters on trends in genetics, technologies, statistics and finances; a handy glossary; and thorough indexes. For the first time, in one carefully-researched volume, you'll get all of the data you need. Topics include: biotechnology funding and investments; activities in Singapore, China and India; FDA; gene therapies; personalized medicine; systems biology; clinical trials; stem cells; therapeutic cloning; nanotechnology; agricultural biotechnology (GM seeds); drug delivery systems; and ethical issues. The book includes complete profiles on 350 top Biotech & Genetics companies, our own unique list of companies that are the leaders in biotechnology. All of the corporate profile information is indexed and cross-indexed. Includes contact names, addresses, Internet addresses, fax numbers and toll-free numbers, plus growth and hiring plans, finances, research, marketing, technology, acquisitions and much more for each firm. You'll find a complete overview, industry analysis and market research report in one superb, value-priced package.
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
- Introduction 1
- How to Use This Book 3
- Chapter 1: Major Trends Affecting the Biotech & Genetics Industry 7
- 1) The State of the Biotechnology Industry Today 7
- 2) A Short History of Biotechnology 11
- 3) Ethanol Production Soared, But U.S. Federal Subsidy Expires 13
- 4) Cellulosic Ethanol Makes Slow Commercial Progress 14
- 5) Major Drug Companies Acquire or Partner With Smaller Biotech Firms 15
- 6) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development 15
- 7) Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance 17
- 8) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing 19
- 9) Vaccines and Viruses in Drug Delivery 20
- 10) New Blockbuster Drugs Come to Market/ Drug Prices Soar 20
- 11) Generic Drugs Have Biggest Market Share by Unit Volume, but not by Total Revenues 22
- 12) Coupons and Other Marketing Schemes Obscure the Retail Prices of Drugs in the U.S., Which Are Vastly Higher than Prices Paid in Other Nations 22
- 13) Biotech and Orphan Drugs Create New Revenues for Drug Firms 24
- 14) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce 24
- 15) Stem Cells—Multiple Sources Stem from New Technologies 26
- 16) Government Support for Stem Cell Research Evolves 26
- 17) Stem Cells—Therapeutic Cloning Techniques Advance 27
- 18) Stem Cells—A New Era of Tissue Replacement Takes Shape 28
- 19) Nanotechnology Converges with Biotech 29
- 20) Genetically Modified (GM) Seeds and Crops Planted in Dozens of Nations/Agribio R&D Investment Is High 30
- 21) Genetically Modified (GM) Foods Prompt Controversy, Labeling and Legislation 32
- 22) Cloning of Farm Animals/Meat and Cheese Substitutes Created in Laboratories/3-D Printed Food Appears 33
- 23) Selective Breeding, Zinc Fingers, Mutagenesis and Gene-Editing as Alternatives to GMOs 33
- 24) Immunotherapy Promises New Approach to Fighting Cancers 34
- 25) Technology Discussion—Genes and DNA 35
- 26) Technology Discussion—Proteins and Proteomics 36
- 27) Technology Discussion—DNA Chips 36
- 28) Technology Discussion—SNPs (“Snips”) 37
- 29) Technology Discussion—Synthetic Biology 37
- 30) Technology Discussion—Recombinant DNA 38
- 31) Technology Discussion—Polymerase Chain Reaction (PCR) 38
- Chapter 2: Biotech & Genetics Industry Statistics 39
- Biotech Industry Statistics and Market Size Overview 40
- The U.S. Drug Discovery & Approval Process 41
- U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2016 42
- U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2016 43
- Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2016 44
- Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2015-2017 45
- U.S. Exports & Imports of Pharmaceutical Products: 2011-1st Quarter 2017 46
- U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2009-2025 47
- Prescription Drug Expenditures, U.S.: Selected Years, 1965-2025 49
- Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2015 50
- Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2016-2018 51
- Global Area of Biotech Crops by Country: 2016 52
- Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1980-2015 53
- Sales By Geographic Area, PhRMA Member Companies: 2014 54
- Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1980-2015 55
- Domestic U.S. Biopharmaceutical R&D & R&D Abroad Breakdown, PhRMA Member Companies: 2014 56
- Chapter 3: Important Biotech & Genetics Industry Contacts 57
- (Addresses, Phone Numbers and Internet Sites)
- Chapter 4: THE BIOTECH 400: Who They Are and How They Were Chosen 95
- Index of Companies Within Industry Groups 96
- Alphabetical Index 105
- Index of U.S. Headquarters Location by State 108
- Index of Non-U.S. Headquarters Location by Country 111
- Individual Profiles on Each of THE BIOTECH 400 115
- Additional Indexes
- Index of Hot Spots for Advancement for Women/Minorities 498
- Index by Subsidiaries, Brand Names and Selected Affiliations 500
- A Short Biotech & Genetics Industry Glossary 519
